Renin-Angiotensin System and Atherothrombotic Disease: From Genes to Treatment
The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
The renin-angiotensin system plays a central role in the pathogenesis of cardiovascular disease. At the molecular and cellular levels, angiotensin II, the main effector peptide of the system, stimulates key components of atherosclerosis. Trials in animals and humans indicate that blocking renin-angiotensin system pathways decreases atherosclerotic plaque progression and ischemic events. This review provides a broad overview of the entire role of the renin-angiotensin system in atherothrombotic disease, ranging from molecular pathways to human genetics to the latest clinical trials.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The SOLVD Investigators* (1991) · New England Journal of Medicine · doi:10.1056/nejm199108013250501 · Cited by 8,029
Pfeffer, M. A., Braunwald, E., Moyé, L. A., Basta, L., Brown, E. J., Cuddy, T. E., Davis, B. R., Geltman, E. M., Goldman, S., Flaker, G. C., et al. (1992) · New England Journal of Medicine · doi:10.1056/nejm199209033271001 · Cited by 5,911
The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group (2002) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.288.23.2981 · Cited by 5,664
Rigat, B., Hubert, C., Alhenc-Gelas, F., Cambien, F., Corvol, P., & Soubrier, F. (1990) · Journal of Clinical Investigation · doi:10.1172/jci114844 · Cited by 3,767 · cited 3×
“The most widely studied polymorphism in the RAS is an insertion (I)/deletion (D) polymorphism in ACE.”
BackgroundInfluential(1992) · New England Journal of Medicine · doi:10.1056/nejm199209033271003 · Cited by 3,725
Angiotensin II stimulates NADH and NADPH oxidase activity in cultured vascular smooth muscle cells.
Griendling, K. K., Minieri, C. A., Ollerenshaw, J. D., & Alexander, R. W. (1994) · Circulation Research · doi:10.1161/01.res.74.6.1141 · Cited by 2,735
Wing, L. M. H., Reid, C. M., Ryan, P., Beilin, L. J., Brown, M. A., Jennings, G. L. R., Johnston, C. I., McNeil, J. J., Macdonald, G. J., Marley, J. E., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa021716 · Cited by 1,130
Lonn, E. M., Yusuf, S., Dzavik, V., Doris, C. I., Yi, Q., Smith, S., Moore-Cox, A., Bosch, J., Riley, W. A., & Teo, K. K. (2001) · Circulation · doi:10.1161/01.cir.103.7.919 · Cited by 712
Smith, S. C., Blair, S. N., Bonow, R. O., Brass, L. M., Cerqueira, M. D., Dracup, K., Fuster, V., Gotto, A., Grundy, S. M., Miller, N. H., et al. (2001) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(01)01682-5 · Cited by 691 · cited 1×
“Established indications for pharmacologic inhibition of the RAS include hypertension, left ventricular dysfunction, acute myocardial infarction (MI), diabetic nephropathy, and atherosclerosis.(2,3) During the past decade, the pathophysiologic understanding of the impact of the RAS has expanded and shifted.”
Background
Cited by
Tikellis, C., & Thomas, M. C. (2012) · International Journal of Peptides · doi:10.1155/2012/256294 · Cited by 624
Dzau, V. J., Antman, E. M., Black, H. R., Hayes, D. L., Manson, J. E., Plutzky, J., Popma, J. J., & Stevenson, W. (2006) · Circulation · doi:10.1161/circulationaha.106.655688 · Cited by 437
Kendrick, J., Targher, G., Smits, G., & Chonchol, M. (2009) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2008.10.033 · Cited by 435
Angiotensin-converting enzyme inhibitors and aortic rupture: a population-based case-control study
Hackam, D. G., Thiruchelvam, D., & Redelmeier, D. A. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69250-7 · Cited by 298
Thomas, M. C., Pickering, R. J., Tsorotes, D., Koitka, A., Sheehy, K., Bernardi, S., Toffoli, B., Nguyen-Huu, T.-P., Head, G. A., Fu, Y., et al. (2010) · Circulation Research · doi:10.1161/circresaha.110.219279 · Cited by 232
“For example, ACE2 is able to cleave the C-terminal amino acid from vasoactive bradykinin (1-8) (also known as des-Arg9-bradykinin) to form the inactive peptide, bradykinin (1-7) and metabolize des-Arg-kallidin (also known as des-Arg10 Lys-bradykinin).”
BackgroundShepherd, A. I., Wilkerson, D. P., Dobson, L., Kelly, J., Winyard, P. G., Jones, A. M., Benjamin, N., Shore, A. C., & Gilchrist, M. (2015) · Nitric Oxide · doi:10.1016/j.niox.2015.01.002 · Cited by 88
“There is conflicting evidence to suggest that ACEi/ARBs can alter the bioavailability of NOx with some studies showing reduction [40] and others proposing increases [41,42].”
BackgroundSahara, M., Ikutomi, M., Morita, T., Minami, Y., Nakajima, T., Hirata, Y., Nagai, R., & Sata, M. (2014) · Cardiovascular Research · doi:10.1093/cvr/cvt245 · Cited by 74
Devaux, C. A., & Camoin-Jau, L. (2022) · Frontiers in Microbiology · doi:10.3389/fmicb.2022.1042200 · Cited by 20
Metadata
- Authors
- Jacoby, D. S., & Rader, D. J.
- Venue
- Archives of Internal Medicine
- Publisher
- American Medical Association (AMA)
- Published
- 2003-05-26
- Volume
- 163
- Issue
- 10
- Pages
- 1155
- ISSN
- 0003-9926
- OpenAlex
- W2088609718
- Cited by
- 118
- References
- 11
- FWCI
- 7.96
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.